AU2007252183B2 - Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof - Google Patents
Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof Download PDFInfo
- Publication number
- AU2007252183B2 AU2007252183B2 AU2007252183A AU2007252183A AU2007252183B2 AU 2007252183 B2 AU2007252183 B2 AU 2007252183B2 AU 2007252183 A AU2007252183 A AU 2007252183A AU 2007252183 A AU2007252183 A AU 2007252183A AU 2007252183 B2 AU2007252183 B2 AU 2007252183B2
- Authority
- AU
- Australia
- Prior art keywords
- solution
- ginsenoside
- adjuvant
- water
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- RWXIFXNRCLMQCD-CZIWJLDFSA-N (20R)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-CZIWJLDFSA-N 0.000 title claims abstract description 108
- XIRZPICFRDZXPF-GCIIHGAUSA-N 20(R)-Ginsenoside Rg3 Natural products CC(=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]6O)C(C)(C)[C@@H]4[C@@H](O)C[C@@]23C)C XIRZPICFRDZXPF-GCIIHGAUSA-N 0.000 title claims abstract description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title claims description 69
- 230000008569 process Effects 0.000 title claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 90
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 53
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 53
- 239000002904 solvent Substances 0.000 claims abstract description 33
- 239000000243 solution Substances 0.000 claims description 197
- 239000000203 mixture Substances 0.000 claims description 116
- 238000002347 injection Methods 0.000 claims description 103
- 239000007924 injection Substances 0.000 claims description 103
- 239000002671 adjuvant Substances 0.000 claims description 96
- 229920000858 Cyclodextrin Polymers 0.000 claims description 71
- 239000000843 powder Substances 0.000 claims description 58
- 238000002360 preparation method Methods 0.000 claims description 54
- 239000007864 aqueous solution Substances 0.000 claims description 44
- 239000012528 membrane Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 12
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000002510 pyrogen Substances 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 7
- 229960003964 deoxycholic acid Drugs 0.000 claims description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 3
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 102
- 241000699670 Mus sp. Species 0.000 description 59
- 241001465754 Metazoa Species 0.000 description 50
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 47
- 239000013642 negative control Substances 0.000 description 32
- 239000008187 granular material Substances 0.000 description 31
- 239000002775 capsule Substances 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 239000008176 lyophilized powder Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 24
- 206010052428 Wound Diseases 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 23
- 238000004166 bioassay Methods 0.000 description 23
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000004044 response Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 239000006285 cell suspension Substances 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 230000009182 swimming Effects 0.000 description 13
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 12
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 12
- 229960002646 scopolamine Drugs 0.000 description 12
- 235000014655 lactic acid Nutrition 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 206010057249 Phagocytosis Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000008782 phagocytosis Effects 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 7
- 238000012449 Kunming mouse Methods 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 230000000118 anti-neoplastic effect Effects 0.000 description 7
- 230000009194 climbing Effects 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000013401 experimental design Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000003791 organic solvent mixture Substances 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 206010048038 Wound infection Diseases 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 4
- 230000002001 anti-metastasis Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 239000004552 water soluble powder Substances 0.000 description 4
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CKUVNOCSBYYHIS-SUEBGMEDSA-N (2r,3r,4s,5s,6r)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-SUEBGMEDSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JGUQDUKBUKFFRO-GGWOSOGESA-N (NE)-N-[(3E)-3-hydroxyiminobutan-2-ylidene]hydroxylamine Chemical compound O\N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-GGWOSOGESA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241001433070 Xiphoides Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- -1 dropping Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100466172A CN1883492B (zh) | 2006-05-22 | 2006-05-22 | 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法 |
| CN200610046617.2 | 2006-05-22 | ||
| PCT/CN2007/001635 WO2007134534A1 (fr) | 2006-05-22 | 2007-05-18 | Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007252183A1 AU2007252183A1 (en) | 2007-11-29 |
| AU2007252183B2 true AU2007252183B2 (en) | 2013-07-11 |
Family
ID=37581875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007252183A Ceased AU2007252183B2 (en) | 2006-05-22 | 2007-05-18 | Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8487090B2 (https=) |
| EP (1) | EP2025339B1 (https=) |
| JP (1) | JP5525814B2 (https=) |
| KR (2) | KR20090014300A (https=) |
| CN (1) | CN1883492B (https=) |
| AU (1) | AU2007252183B2 (https=) |
| CA (1) | CA2653085C (https=) |
| ES (1) | ES2477873T3 (https=) |
| RU (1) | RU2432164C2 (https=) |
| WO (1) | WO2007134534A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011512404A (ja) * | 2008-02-19 | 2011-04-21 | ユニジェン インク． | 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物 |
| CN101530389B (zh) * | 2008-03-11 | 2012-02-15 | 沈阳市万嘉生物技术研究所 | 人参皂苷Rg3磷脂复合物及其制备方法 |
| CN102091114B (zh) * | 2009-12-15 | 2014-11-26 | 河北以岭医药研究院有限公司 | 一种中药冻干注射剂及其制备方法 |
| KR100992800B1 (ko) * | 2010-05-14 | 2010-11-08 | 주식회사 지씨에이치앤피 | 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법 |
| CN103845280B (zh) * | 2012-11-30 | 2017-04-12 | 富力 | 一种20(R)‑人参皂苷Rg3外用制剂、制法与用途 |
| CN103845348B (zh) * | 2012-11-30 | 2016-07-13 | 富力 | 20(R)-人参皂苷Rg3在制备痛经药物中的应用 |
| KR101316095B1 (ko) * | 2013-01-30 | 2013-10-11 | 경희대학교 산학협력단 | 진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물 |
| KR102021463B1 (ko) * | 2013-04-24 | 2019-09-16 | (주)아모레퍼시픽 | 진세노사이드 Rg3를 함유하는 피부 외용제 조성물 |
| KR101595426B1 (ko) | 2013-08-30 | 2016-02-18 | (주)녹십자웰빙 | 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물 |
| CN104643058A (zh) * | 2013-11-21 | 2015-05-27 | 富力 | 20(R)-人参皂苷Rg3在制备改善或/和治疗肝硬化疾病的药物中的应用 |
| CN104644658A (zh) * | 2013-11-22 | 2015-05-27 | 富力 | 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物 |
| CN105012315A (zh) * | 2014-04-24 | 2015-11-04 | 上海中医药大学 | 20(r)-原人参二醇的医药用途 |
| CN105777838A (zh) * | 2014-12-17 | 2016-07-20 | 富力 | 20(R)-人参皂苷Rg3衍生物、制备方法及其应用 |
| CN105982906A (zh) * | 2015-02-11 | 2016-10-05 | 富力 | 20(R)-人参皂苷Rg3在制备缓解或/和治疗类风湿病症的药物或保健品中的应用及药物 |
| KR101772759B1 (ko) | 2015-09-25 | 2017-08-30 | 순천향대학교 산학협력단 | 안정화된 무정형의 20(R)-진세노사이드 Rg3, 이의 제조방법 및 이를 함유하는 약제학적 제제 |
| CN105878206A (zh) * | 2016-03-31 | 2016-08-24 | 北京万全德众医药生物技术有限公司 | 一种人参皂苷Rg3的软胶囊及其制备方法 |
| KR20180000379A (ko) * | 2016-06-22 | 2018-01-03 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 f1을 유효성분으로 포함하는 면역증강용 조성물 |
| CN108310106A (zh) * | 2018-03-30 | 2018-07-24 | 吉林省恒实传食品科技发展有限公司 | 一种补肾填髓、健脑益智、辅助改善记忆的中药组合物及其应用 |
| KR20200112012A (ko) * | 2019-03-20 | 2020-10-05 | 순천대학교 산학협력단 | (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물 |
| CN111686104A (zh) * | 2020-07-01 | 2020-09-22 | 香港浸会大学深圳研究院 | 小白菊内酯、木犀草素、金圣草素和人参皂苷Rg3的新用途 |
| CN112245443A (zh) * | 2020-08-25 | 2021-01-22 | 富力 | 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用 |
| CN116077442A (zh) * | 2023-01-06 | 2023-05-09 | 吉林大学 | 一种含有人参皂苷Rg3的纳米颗粒及其制备方法和应用 |
| KR102756809B1 (ko) * | 2023-10-13 | 2025-01-22 | 표재성 | 난용성 진세노사이드의 수용해도를 높인 조성물, 이를 이용한 화장품조성물 및 건강기능식품 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1526405A (zh) * | 2003-01-06 | 2004-09-08 | 山东绿叶天然药物研究开发有限公司 | 抗肿瘤的人参皂苷Rg3注射剂及其制备方法 |
| CN1569012A (zh) * | 2003-07-24 | 2005-01-26 | 山东绿叶天然药物研究开发有限公司 | 20(R)－人参皂苷－Rg3在制备治疗或预防高血压的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1186015C (zh) | 2001-01-18 | 2005-01-26 | 天津实验动物中心 | 用于冠心病心绞痛的中药复方口腔贴膜 |
| CN1167734C (zh) * | 2001-07-02 | 2004-09-22 | 董英杰 | 人参皂甙Rg3羟丙基-β-环糊精包合物及制剂和制备方法 |
| CN1569011A (zh) | 2003-07-24 | 2005-01-26 | 山东绿叶天然药物研究开发有限公司 | 20（R）－人参皂苷－Rg3在制备治疗或预防心脑血管疾病的药物中的应用 |
| WO2005034963A1 (en) * | 2003-10-15 | 2005-04-21 | Panagin Pharmaceuticals Inc. | USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER |
-
2006
- 2006-05-22 CN CN2006100466172A patent/CN1883492B/zh active Active
-
2007
- 2007-05-18 KR KR1020087031196A patent/KR20090014300A/ko not_active Ceased
- 2007-05-18 EP EP07721208.2A patent/EP2025339B1/en active Active
- 2007-05-18 JP JP2009511321A patent/JP5525814B2/ja not_active Expired - Fee Related
- 2007-05-18 RU RU2008150468/15A patent/RU2432164C2/ru active
- 2007-05-18 ES ES07721208.2T patent/ES2477873T3/es active Active
- 2007-05-18 KR KR1020127011500A patent/KR101221680B1/ko not_active Expired - Fee Related
- 2007-05-18 WO PCT/CN2007/001635 patent/WO2007134534A1/zh not_active Ceased
- 2007-05-18 AU AU2007252183A patent/AU2007252183B2/en not_active Ceased
- 2007-05-18 CA CA2653085A patent/CA2653085C/en active Active
- 2007-05-18 US US12/301,996 patent/US8487090B2/en active Active
-
2013
- 2013-07-12 US US13/941,106 patent/US9333215B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1526405A (zh) * | 2003-01-06 | 2004-09-08 | 山东绿叶天然药物研究开发有限公司 | 抗肿瘤的人参皂苷Rg3注射剂及其制备方法 |
| CN1569012A (zh) * | 2003-07-24 | 2005-01-26 | 山东绿叶天然药物研究开发有限公司 | 20(R)－人参皂苷－Rg3在制备治疗或预防高血压的药物中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| Kiefer, D et al (2003) American Family Physician. Volume 68. Pages 1539-1542 * |
| Qian, T et al (2005) Journal of Chromatography B. Volume 816. Pages 223-232 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2025339A1 (en) | 2009-02-18 |
| RU2008150468A (ru) | 2010-06-27 |
| JP2009537572A (ja) | 2009-10-29 |
| KR20120054664A (ko) | 2012-05-30 |
| US9333215B2 (en) | 2016-05-10 |
| CA2653085C (en) | 2016-01-19 |
| US20130345156A1 (en) | 2013-12-26 |
| CN1883492B (zh) | 2010-07-28 |
| CN1883492A (zh) | 2006-12-27 |
| ES2477873T3 (es) | 2014-07-18 |
| KR101221680B1 (ko) | 2013-01-11 |
| KR20090014300A (ko) | 2009-02-09 |
| JP5525814B2 (ja) | 2014-06-18 |
| AU2007252183A1 (en) | 2007-11-29 |
| US20120149656A1 (en) | 2012-06-14 |
| US8487090B2 (en) | 2013-07-16 |
| WO2007134534A1 (fr) | 2007-11-29 |
| RU2432164C2 (ru) | 2011-10-27 |
| EP2025339A4 (en) | 2013-01-16 |
| CA2653085A1 (en) | 2007-11-29 |
| EP2025339B1 (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007252183B2 (en) | Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof | |
| Zhaojie et al. | Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability | |
| US8871253B2 (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| WO2017162108A1 (zh) | 一种柱芳烃类复合物、其制备方法、药物组合物和用途 | |
| US20150030672A1 (en) | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt | |
| CN104844600B (zh) | 一种他达拉非化合物、及其组合物 | |
| Saleem et al. | Nanoscale celecoxib prodrugs: As efficient anti-inflammatory principles | |
| CN107049944A (zh) | 一种可实现索拉非尼和姜黄素同时给药的聚合物胶束及其制备方法 | |
| EP2934593B1 (en) | Cabazitaxel composition | |
| CN115124532B (zh) | 大黄酸与苦参碱共晶物及制备方法和其组合物与用途 | |
| CN113197854A (zh) | 一种氟康唑三元纳米胶束及其制备方法 | |
| US8859527B2 (en) | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof | |
| US7863337B2 (en) | Use of triacontanol in preparation of medicaments for treatment of cancers | |
| CN110464708A (zh) | 一种螺旋藻纳米制剂及其制备方法 | |
| CN106606786A (zh) | 一种含艾沙康唑的药物组合物 | |
| CN115804852A (zh) | 一种叶酸修饰青藤碱人血清白蛋白纳米粒及其制备方法和应用 | |
| CN108785249A (zh) | 含三苯双脒纳米超微粉的剂型 | |
| CN120392771A (zh) | 小分子化合物及其在制备治疗24p3R介导的疾病的药物中的应用 | |
| CN104739828B (zh) | 一种厄他培南钠药物组合物及其制备方法 | |
| CN121287925A (zh) | 一种治疗抑郁症的脑靶向纳米制剂及其制备方法与应用 | |
| CN119192264A (zh) | 一种4-羟甲基苯硼酸修饰的两性霉素b衍生物及其制备方法和应用 | |
| CN110117279A (zh) | (13aS)-3-新戊酰氧基-6,7-二甲氧基菲并吲哚里西啶的晶B型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: DALIAN FUSHENG NATURAL MEDICINE DEVELOPMENT CO. LT Free format text: FORMER APPLICANT(S): FU, LI |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |